[HTML][HTML] Avidity in antibody effector functions and biotherapeutic drug design
SC Oostindie, GA Lazar, J Schuurman… - Nature Reviews Drug …, 2022 - nature.com
Antibodies are the cardinal effector molecules of the immune system and are being
leveraged with enormous success as biotherapeutic drugs. A key part of the adaptive …
leveraged with enormous success as biotherapeutic drugs. A key part of the adaptive …
[HTML][HTML] Malaria vaccines since 2000: progress, priorities, products
PE Duffy, J Patrick Gorres - npj Vaccines, 2020 - nature.com
Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …
[HTML][HTML] A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver
LT Wang, LS Pereira, Y Flores-Garcia, J O'Connor… - Immunity, 2020 - cell.com
Discovering potent human monoclonal antibodies (mAbs) targeting the Plasmodium
falciparum circumsporozoite protein (PfCSP) on sporozoites (SPZ) and elucidating their …
falciparum circumsporozoite protein (PfCSP) on sporozoites (SPZ) and elucidating their …
Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab
Cluster of differentiation 20 (CD20) is a B cell membrane protein that is targeted by
monoclonal antibodies for the treatment of malignancies and autoimmune disorders but …
monoclonal antibodies for the treatment of malignancies and autoimmune disorders but …
[HTML][HTML] A candidate antibody drug for prevention of malaria
KL Williams, S Guerrero, Y Flores-Garcia, D Kim… - Nature medicine, 2024 - nature.com
Over 75% of malaria-attributable deaths occur in children under the age of 5 years.
However, the first malaria vaccine recommended by the World Health Organization (WHO) …
However, the first malaria vaccine recommended by the World Health Organization (WHO) …
[HTML][HTML] Affinity-matured homotypic interactions induce spectrum of PfCSP structures that influence protection from malaria infection
The generation of high-quality antibody responses to Plasmodium falciparum (Pf)
circumsporozoite protein (PfCSP), the primary surface antigen of Pf sporozoites, is …
circumsporozoite protein (PfCSP), the primary surface antigen of Pf sporozoites, is …
Antibodies against Plasmodium falciparum malaria at the molecular level
JP Julien, H Wardemann - Nature Reviews Immunology, 2019 - nature.com
Malaria is a vector-borne disease of global importance, with the vast majority of its life-
threatening cases caused by infection with Plasmodium falciparum parasites. Repeated …
threatening cases caused by infection with Plasmodium falciparum parasites. Repeated …
[HTML][HTML] Heterotypic interactions drive antibody synergy against a malaria vaccine candidate
RJ Ragotte, D Pulido, AM Lias, D Quinkert… - Nature …, 2022 - nature.com
Understanding mechanisms of antibody synergy is important for vaccine design and
antibody cocktail development. Examples of synergy between antibodies are well …
antibody cocktail development. Examples of synergy between antibodies are well …
Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs
The circumsporozoite protein of the human malaria parasite Plasmodium falciparum
(PfCSP) is the main target of antibodies that prevent the infection and disease, as shown in …
(PfCSP) is the main target of antibodies that prevent the infection and disease, as shown in …
[HTML][HTML] A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum
Potent and durable vaccine responses will be required for control of malaria caused by
Plasmodium falciparum (Pf). RTS, S/AS01 is the first, and to date, the only vaccine that has …
Plasmodium falciparum (Pf). RTS, S/AS01 is the first, and to date, the only vaccine that has …